Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $5

Benzinga · 03/25 10:40
Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Neutral and raises the price target from $4 to $5.